Vijay Pande Leaves a16z to Launch Boutique AI-Biotech Venture Firm VZVC

Pande, a former Stanford chemistry professor best known for creating the distributed-computing project Folding@home, was recruited by Marc Andreessen and Ben Horowitz a dozen years ago to lead their newly formed healthcare investing practice — a category the firm had deliberately avoided for its first five years. Over the next decade-plus, he grew that practice to manage close to $4 billion.

His departure last June was unexpected. The new firm, VZVC, co-founded with longtime investor Zach Werner, is built around a handful of concentrated bets annually rather than dozens. It operates without associates and relies heavily on AI for its day-to-day operations.

In a conversation, Pande characterised biology as shifting from a "science of discovery" to something that can be engineered. He said AI and machine learning enable computers to understand complex biological systems, identify drug targets, design drugs, and even assist in clinical trials — the most expensive part of the process.

On clinical trial costs, Pande pushed back on the idea that synthetic data is already making them significantly cheaper, calling that "very much an aspiration." He noted that while the cost and time to reach clinical trials has shrunk, especially with AI, running a trial can still cost hundreds of millions of dollars. The probability of a drug progressing from first to third trial successfully is just 20 percent, he said. The main reason for failure, he argued, is that drugs are designed on animal models that are not very predictive of humans. "The AI model is not going to be perfect, but it's going to be way better than any animal model would be," Pande said.

He also discussed precision medicine, arguing that patients would benefit if doctors could prescribe the right drug on the first try rather than cycling through ineffective treatments. However, he noted a key challenge unique to biology: unlike text, biological data cannot be scraped off the internet, so nearly every company builds its own walled-off dataset. This raises questions about who gets access to the advances AI promises in medicine.

Why This Matters

Pande's move from a mega-fund to a lean, AI-driven boutique signals a potential shift in how venture capital operates in deep-tech fields — focusing on concentrated bets rather than portfolio diversification.
His views on AI in drug development highlight both the promise and the persistent cost barriers in clinical trials, which determine drug pricing and patient access.
The data bottleneck he describes — proprietary biological datasets that cannot be scraped — could determine whether AI-driven medicine benefits a few well-funded companies or the broader healthcare system.

Background

Vijay Pande is a prominent figure at the intersection of AI and biology. He led a16z's healthcare investing for over a decade, building one of the largest venture practices in the sector. His academic background includes founding Folding@home, a distributed-computing project that used home PCs to simulate protein folding. The new firm VZVC appears to be an experiment in lean, AI-native venture capital, operating without the traditional associate pyramid and relying on algorithmic tools for deal flow and operations.

Key Perspectives

Vijay Pande (VZVC co-founder): Sees AI as a transformative tool that can turn biology from a discovery science into an engineering discipline, potentially saving time and money in drug development. He advocates for a focused approach with just a few bets per year. Critics/Skeptics: The high failure rate of clinical trials (80% from Phase I to Phase III) and the enormous costs remain daunting. The promise of AI may be oversold if the data limitations — proprietary, non-scrapable biological datasets — prevent the kind of rapid learning seen in other AI domains. Industry observers: The shift toward smaller, more concentrated venture funds could be a response to market conditions, or a genuine innovation in how to back risky, capital-intensive technologies like AI-driven biotech.

What to Watch

How many investments VZVC makes in its first year and their performance relative to traditional large-portfolio funds.
Whether Pande's approach to using AI in operations becomes a model for other venture firms.
The development of AI models that can learn from small, proprietary biological datasets — a technical hurdle that, if solved, could unlock the precision medicine era Pande envisions.

ZOTPAPER